DiaMedica CFO granted 162,000 stock options

DiaMedica Therapeutics Inc. reported that its CFO and Secretary, Kellen Scott, received a grant of stock options classified as a derivative security.

Rhea-AI Filing Summary

DiaMedica Therapeutics Inc. reported that its CFO and Secretary, Kellen Scott, received a grant of stock options classified as a derivative security. The award covers 162,000 stock options, each giving the right to buy one voting common share at an exercise price of $5.84 per share.

The options were granted as compensation, not as an open-market purchase, and are held directly. They are scheduled to vest 25% on the one-year anniversary of the grant date, with the remaining options vesting in twelve equal quarterly installments, and they expire on June 1, 2036.

Insider Trade Summary

Grant/Award: 162,000 shares

Grant/Award 1 txn

Insider Kellen Scott

Role CFO & Secretary

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (right to buy)	162,000	$0.00	$0.00

Holdings After Transaction: Stock Option (right to buy) — 162,000 contracts (Direct)

Footnotes (1)

1. F1. Scheduled to vest with respect to 25% of the shares on the one-year anniversary of the grant date, with the remaining shares scheduled to vest in twelve equivalent quarterly installments.

Key Figures

Options granted: 162,000 options Exercise price: $5.84 per share Post-transaction derivative holdings: 162,000 options +3 more

6 metrics

Options granted 162,000 options Stock Option (right to buy) award to CFO

Exercise price $5.84 per share Conversion or exercise price for voting common shares

Post-transaction derivative holdings 162,000 options Total derivative securities following transaction

Expiration date June 1, 2036 Option expiration for this grant

Initial vesting 25% after one year First vesting tranche on grant anniversary

Remaining vesting schedule 12 quarterly installments Vesting of remaining 75% of options

Key Terms

Stock Option (right to buy), Grant, award, or other acquisition, voting common shares, vest, +1 more

5 terms

Stock Option (right to buy) financial

"security_title: Stock Option (right to buy)"

Grant, award, or other acquisition financial

"transaction_code_description: Grant, award, or other acquisition"

voting common shares financial

"underlying_security_title: Voting Common Shares"

vest financial

"Scheduled to vest with respect to 25% of the shares on the one-year anniversary"

A vest is the process by which an employee earns the right to receive certain benefits or ownership interests, such as stock or retirement funds, over time. It’s similar to earning a reward gradually, ensuring that the benefit becomes fully yours only after a set period or meeting specific conditions. This makes it important for investors because it determines when they can actually claim or use those benefits.

quarterly installments financial

"with the remaining shares scheduled to vest in twelve equivalent quarterly installments"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did DiaMedica Therapeutics (DMAC) CFO receive in this Form 4?

DiaMedica Therapeutics’ CFO, Kellen Scott, received a grant of 162,000 stock options. Each option is a right to buy one voting common share as part of compensation, rather than an open-market share purchase.

What is the exercise price of the DiaMedica Therapeutics (DMAC) options granted?

The granted stock options have an exercise price of $5.84 per share. This means Kellen Scott can buy DiaMedica voting common shares at $5.84 when the options vest and are exercised, regardless of the market price then.

How do the DiaMedica Therapeutics (DMAC) CFO’s new options vest?

The options are scheduled to vest with 25% on the one-year anniversary of the grant date. The remaining 75% will then vest in twelve equivalent quarterly installments, aligning vesting with a multi-year service period.

When do the DiaMedica Therapeutics (DMAC) stock options granted to the CFO expire?

The stock options granted to Kellen Scott expire on June 1, 2036. After this expiration date, any unexercised options become worthless and can no longer be used to purchase DiaMedica voting common shares.

Is the DiaMedica Therapeutics (DMAC) Form 4 transaction a stock purchase or compensation grant?

The Form 4 reflects a compensation-related grant of stock options, not an open-market stock purchase. The transaction code is “A,” indicating a grant or award acquisition of options with no cash paid at grant.

How many DiaMedica Therapeutics (DMAC) derivative securities does the CFO hold after this grant?

Following this transaction, Kellen Scott holds 162,000 stock options as reported. These options are held directly and are tied one-for-one to underlying voting common shares, subject to the vesting schedule and the 2036 expiration.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 06/03/2026 - 05:23 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Kellen Scott

(Last) (First) (Middle)

301 CARLSON PARKWAY

SUITE 210

(Street)

MINNEAPOLIS MINNESOTA 55305

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
DiaMedica Therapeutics Inc. [ DMAC ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	CFO & Secretary

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/01/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (right to buy)	$5.84	06/01/2026		A		162,000		(1)	06/01/2036	Voting Common Shares	162,000	$0	162,000	D

Explanation of Responses:

1. Scheduled to vest with respect to 25% of the shares on the one-year anniversary of the grant date, with the remaining shares scheduled to vest in twelve equivalent quarterly installments.

	/s/ Joshua L. Colburn, attorney-in-fact	06/03/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)